News & Updates

Long-term dermatological surveillance valuable after liver transplant

30 Aug 2021 by

Though skin cancer incidence is low, liver transplant recipients may still benefit from long-term dermatological surveillance to help monitor malignancies and infections, according to a recent Singapore study.

Long-term dermatological surveillance valuable after liver transplant

30 Aug 2021

Nivolumab shows promise for advanced HCC

28 Aug 2021

Nivolumab shows clinical activity in patients with advanced hepatocellular carcinoma (aHCC) with Child-Pugh B status, accompanied by a favourable safety profile and manageable side-effects, a recent study has found.

Nivolumab shows promise for advanced HCC

28 Aug 2021

Acute viral hepatitis burden heaviest in low-income countries

26 Aug 2021

Socioeconomic development is inversely correlated with acute viral hepatitis (AVH), such that the disease burden is highest among low-income countries, a recent study has found.

Acute viral hepatitis burden heaviest in low-income countries

26 Aug 2021

Obesity, NAFLD may disqualify potential liver transplant donors

21 Aug 2021

Obesity and nonalcoholic fatty liver disease (NAFLD) may disqualify potential donors from being suitable for living donor liver transplantation (LDLT), a recent study has found.

Obesity, NAFLD may disqualify potential liver transplant donors

21 Aug 2021

Universal DAA access tied to reduced HCV prevalence in PLHIV

20 Aug 2021 by

Universal access to direct-acting antivirals (DAAs) may have led to the low prevalence of hepatitis C viraemia among people living with HIV (PLHIV) in The Netherlands, according to a study presented at IAS 2021.

Universal DAA access tied to reduced HCV prevalence in PLHIV

20 Aug 2021

Tenofovir alafenamide may prevent HBV mother-to-child transmission

19 Aug 2021 by

Tenofovir alafenamide (TAF), administered during the second or third trimester of pregnancy, may prevent mother-to-child transmission (MTCT) of hepatitis B virus (HBV) infection, according to two studies presented as posters at ILC 2021.

Tenofovir alafenamide may prevent HBV mother-to-child transmission

19 Aug 2021

Adding amoxicillin/clavulanate to prednisolone yields no survival benefit in severe alcoholic hepatitis

06 Aug 2021 by

The addition of amoxicillin/clavulanate to prednisolone does not extend survival among patients with severe alcoholic hepatitis, though it may reduce infection risk, according to a French study presented at ILC 2021.

Adding amoxicillin/clavulanate to prednisolone yields no survival benefit in severe alcoholic hepatitis

06 Aug 2021

Thiopurines do not exacerbate risk of post-ERC pancreatitis

05 Aug 2021

In patients with primary sclerosing cholangitis, past or present use of thiopurines does not increase the risk of post-endoscopic retrograde cholangiography (ERC) pancreatitis, a recent study has found.

Thiopurines do not exacerbate risk of post-ERC pancreatitis

05 Aug 2021

Original New Drug Application Approvals by US FDA (16 - 31 July 2021)

02 Aug 2021

New drug applications approved by US FDA as of 16-31 July 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 31 July 2021)

02 Aug 2021

TVB-2640 impresses in nonalcoholic steatohepatitis

01 Aug 2021

Use of the fatty acid synthase (FASN) inhibitor TVB-2640 in the treatment of patients with nonalcoholic steatohepatitis (NASH) yields dose-dependent improvements in liver fat as well as biochemical, inflammatory, and fibrotic biomarkers, according to the results of the phase IIa trial 3V2640-CLIN-005 (FASCINATE-1).

TVB-2640 impresses in nonalcoholic steatohepatitis

01 Aug 2021

News & Updates

Filter by Specialty:

Specialty:

Long-term dermatological surveillance valuable after liver transplant

Long-term dermatological surveillance valuable after liver transplant

Nivolumab shows promise for advanced HCC

Nivolumab shows promise for advanced HCC

Acute viral hepatitis burden heaviest in low-income countries

Acute viral hepatitis burden heaviest in low-income countries

Obesity, NAFLD may disqualify potential liver transplant donors

Obesity, NAFLD may disqualify potential liver transplant donors

Universal DAA access tied to reduced HCV prevalence in PLHIV

Universal DAA access tied to reduced HCV prevalence in PLHIV

Tenofovir alafenamide may prevent HBV mother-to-child transmission

Tenofovir alafenamide may prevent HBV mother-to-child transmission

Adding amoxicillin/clavulanate to prednisolone yields no survival benefit in severe alcoholic hepatitis

Adding amoxicillin/clavulanate to prednisolone yields no survival benefit in severe alcoholic hepatitis

Thiopurines do not exacerbate risk of post-ERC pancreatitis

Thiopurines do not exacerbate risk of post-ERC pancreatitis

Original New Drug Application Approvals by US FDA (16 - 31 July 2021)

Original New Drug Application Approvals by US FDA (16 - 31 July 2021)

TVB-2640 impresses in nonalcoholic steatohepatitis

TVB-2640 impresses in nonalcoholic steatohepatitis